Not a single study
Story checked
Simple urine test could guide kidney-protective treatment choices in type 2 diabetes (opens in a new tab)
medicalxpress.com · 2026-09-16
Short answer
Not a single studyNo clear answer.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Simple urine test could guide kidney-protective treatment choices in type 2 diabetes
medicalxpress.com · 2026-09-16
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
This story isn't reporting one study.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Open claim evidenceSearch result
No single source study.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Source layer
The paper behind the story
The source record for this check.
The research anchor for the report.
- Also referencedpresented as the new finding
Renal outcomes in people with type 2 diabetes with and without albuminuria treated with SGLT-2 inhibitors and GLP-1 receptor agonists: target trial emulation
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 6Not checkedA new study led by Mass General Brigham researchers found that GLP-1 agonists and SGLT2 inhibitors reduced the risk of kidney deterioration in patients with diabetes who had protein in their urine before treatment.View evidenceHide evidence
As statedreduced the risk of kidney deterioration
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 6Not checkedThe researchers found little evidence of kidney benefit among patients without protein in their urine.View evidenceHide evidence
As statedlittle evidence of kidney benefit
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 6Not checkedSulfonylureas, an older class of diabetes medication, led to faster declines in kidney function in patients with diabetes who didn't have protein in their urine.View evidenceHide evidence
As statedfaster declines in kidney function
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 6Not checkedThe study analyzed medical record data from 75,455 patients with type 2 diabetes across the U.S., including 13,872 who presented with protein in their urine, and followed them for up to five years.View evidenceHide evidence
As stated75,455 patients; 13,872 with protein in urine; up to five years
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 6Not checkedAll patients had moderate cardiovascular risk and were receiving metformin as their primary diabetes medication.View evidenceHide evidence
As statedmoderate cardiovascular risk
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 6Not checkedThe paper was published in the BMJ and is titled 'Renal outcomes in people with type 2 diabetes with and without albuminuria treated with SGLT-2 inhibitors and GLP-1 receptor agonists: target trial emulation.'View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Crossref, Europe PMC · 15 candidate papers
eGFR- and Potassium-Guided Stewardship of SGLT2 Inhibitors and Finerenone in Albuminuric Chronic Kidney Disease Associated with Type 2 Diabetes.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy · 2026 · PubMed
SGLT2 Inhibitor And GLP-1 Receptor Agonist in Type 2 Diabetes Mellitus Patients. Research on Their Cardiovascular Benefits
Highlights in Science, Engineering and Technology · 2023 · Crossref
Renal outcomes associated with sodium-glucose cotransporter 2 inhibitor use in kidney transplant recipients with type 2 or posttransplant diabetes: A propensity score overlap weighting retrospective cohort study.
2026 · Europe PMC
Metabolic phenotype dimensions and longitudinal renal function in type 2 diabetes: a principal component analysis-based approach with UACR integration.
Frontiers in Endocrinology · 2026 · PubMed
Cardiovascular and renal effects of the combination therapy of a GLP-1 receptor agonist and an SGLT2 inhibitor in observational real-life studies
Diabetes & Metabolism · 2025 · Crossref
And 10 more candidates considered.